RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta)
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Recently, we reported that in rhesus monkeys, RU 486 treatment could inhibit the ability of estradiol (E2) to stimulate endometrial regeneration without inhibiting E2-dependent oviductal regeneration. In that work, RU 486 had been administered at the end of an artificial luteal phase when the oviducts were regressed, the endometrium was in a late secretory state, and estrogen and progestin receptors (ER and PR, respectively) were at minimal levels in both organs. In the current work, we administered RU 486 after 2 weeks of estrogen priming when the oviducts were fully differentiated, the endometrium was in a proliferative state, and ER and PR levels were maximal. Our goal was to determine whether the degree to which RU 486 inhibited E2 action in either organ varied depending on their initial state. Spayed rhesus monkeys were primed with E2 for 2 weeks and then treated in four different ways for an additional 2 weeks as follows: I) E2; II) E2 plus P; III) E2, P, and RU 486; and IV) E2 plus RU 486. Menstruation was not induced by any of the four treatments. In group I, continuous treatment with E2 maintained a typical proliferative endometrium with abundant Ki-67-positive cells, low levels of apoptosis, and elevated ER and PR; the oviducts were also maintained in a fully ciliated-secretory state. In group II, P induced a typical progestational secretory state in the endometrium, with few proliferating (Ki-67-positive) epithelial cells, undetectable apoptosis, and decreased ER and PR; as expected, the oviducts were fully regressed, with few Ki-67-positive or ciliated epithelial cells and low levels of ER and PR. In the endometria of monkeys treated with RU 486 and E2, either with (group III) or without (group IV) P, the effects of E2 on wet weight, thickness, and epithelial proliferation were more dramatically inhibited than in our previous study. However, the oviducts of the RU 486-treated animals had remained in a hypertrophied, fully ciliated-secretory state as in our previous study, with elevated ER and nuclear PR, although epithelial proliferation was suppressed. The degree to which RU 486 can inhibit estrogen-dependent growth in the endometrium can apparently be affected by the state of differentiation and/or steroid receptor level at the time the antiprogestin treatment is begun, but this effect is not evident in the oviduct, which shows only modest antiproliferative effects of the RU 486 treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Gerdes, J., Schwab, U., Lemke, H., & Stein, H. (1983) · International Journal of Cancer · doi:10.1002/ijc.2910310104 · Cited by 2,788
Cited by
Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi002 · Cited by 310
Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Whitaker, L. H. R., Murray, A. A., Matthews, R., Shaw, G., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. O. D. (2017) · Human Reproduction · doi:10.1093/humrep/dew359 · Cited by 77
“AR regulation has been implicated in the endometrial anti-proliferative effect observed with mifepristone administration (Slayden and Brenner, 1994).”
Deficiency of Immunophilin FKBP52 Promotes Endometriosis
Hirota, Y., Tranguch, S., Daikoku, T., Hasegawa, A., Osuga, Y., Taketani, Y., & Dey, S. K. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080527 · Cited by 67
“Many studies have shown anti-proliferative roles of PR in the uterus.(7,56) In fact, a previous study using PR null mice found that estrogen is a primary factor that determines the size of ectopic lesions.”
Background
Metadata
- Authors
- Slayden, O. D.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1994-02-01
- Volume
- 78
- Issue
- 2
- Pages
- 440-448
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W1975486822
- Cited by
- 77
- References
- 2
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.